Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Update

Vaccinex, Inc. (NASDAQ:VCNX) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 20,100 shares, an increase of 118.5% from the May 31st total of 9,200 shares. Based on an average daily volume of 18,200 shares, the days-to-cover ratio is currently 1.1 days. Currently, 2.6% of the shares of the company are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Vaccinex stock. Worth Venture Partners LLC increased its stake in shares of Vaccinex, Inc. (NASDAQ:VCNX) by 417.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 717,559 shares of the company’s stock after buying an additional 578,764 shares during the period. Worth Venture Partners LLC owned about 16.31% of Vaccinex worth $811,000 as of its most recent filing with the Securities and Exchange Commission. 50.11% of the stock is currently owned by institutional investors.

Vaccinex Trading Up 5.0 %

Shares of Vaccinex stock traded up $0.31 on Friday, reaching $6.49. 7,230 shares of the stock were exchanged, compared to its average volume of 40,662. Vaccinex has a 1-year low of $4.43 and a 1-year high of $83.56. The business has a fifty day moving average price of $6.00 and a two-hundred day moving average price of $7.50. The firm has a market capitalization of $10.25 million, a PE ratio of -0.08 and a beta of 0.86.

Vaccinex (NASDAQ:VCNX) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($2.94) earnings per share (EPS) for the quarter. The firm had revenue of $0.10 million for the quarter.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.